|
Originally published In Press as doi:10.1074/jbc.M006265200 on August 21, 2000
J. Biol. Chem., Vol. 275, Issue 45, 35063-35069, November 10, 2000
The Human Lysyl-tRNA Synthetase Gene Encodes Both the Cytoplasmic
and Mitochondrial Enzymes by Means of an Unusual Alternative Splicing
of the Primary Transcript*
Elena
Tolkunova,
Hyejeong
Park,
Jun
Xia,
Michael P.
King , and
Edgar
Davidson
From the Department of Biochemistry and Molecular Pharmacology,
Thomas Jefferson University, Philadelphia, Pennsylvania 19107
Received for publication, July 14, 2000, and in revised form, August 16, 2000
 |
ABSTRACT |
Two cDNAs encoding human lysyl-tRNA
synthetase have been identified. One encodes the cytoplasmic form of
the enzyme identified previously. The second cDNA contains the same
sequence but with a 180-bp insertion at the 5'-end of the mRNA.
This results in a predicted protein whose carboxyl 576 amino
acids are identical to those of the cytoplasmic enzyme but with
a different amino terminus of 49 amino acids that contains a putative
mitochondrial targeting sequence. Expression of the two lysyl-tRNA
synthetase-green fluorescent protein gene fusions in a human cell line
confirmed that the cytoplasmic form was targeted to the cytoplasm and
the mitochondrial form to mitochondria. The genomic lysyl-tRNA
synthetase gene consisted of 15 exons. The two isoforms were created by
alternative splicing of the first three exons of the gene. The
cytoplasmic form was created by splicing exon 1 to exon 3. The
inclusion of exon 2 between exons 1 and 3 produced an mRNA encoding
the mitochondrial isoform with an additional upstream small open
reading frame, consisting mainly of a portion of the 5' coding region
of the cytoplasmic isoform. This is the first example of mitochondrial targeting sequence being encoded on the second exon of a gene. Ribonuclease protection analysis showed that the mRNA encoding the
cytoplasmic isoform makes up approximately 70%, and the mitochondrial isoform approximately 30%, of the mature transcripts from the lysyl-tRNA synthetase gene. The mitochondrial form of the enzyme, purified after expression in Escherichia coli,
aminoacylated in vitro transcripts corresponding to both
the cytoplasmic and mitochondrial tRNALys, despite the
difference in the discriminator base sequence in the acceptor stems of
these tRNAs.
 |
INTRODUCTION |
The tRNA synthetases are a group of enzymes responsible for
aminoacylating tRNAs with appropriate amino acids. In recent years, a
considerable amount of information has been obtained about their functions, but there are still a number of uncharacterized members of
this diverse group of enzymes.
Genes encoding lysyl-tRNA synthetases have been cloned from a number of
organisms, and crystal structures have been obtained for one of the two
Escherichia coli lysyl-tRNA synthetases, LysU (1), and the
Thermus thermophilus lysyl-tRNA synthetase (2). The majority
of the lysyl-tRNA synthetases are class II enzymes; however, some
archaebacteria have a class I lysyl-tRNA synthetase (3). The cDNA
encoding the human cytoplasmic lysyl-tRNA synthetase has been described
previously, and the protein purified after expression in E. coli has been characterized (4). In mammals, the cytoplasmic form
is a component of a synthetase complex that contains an additional
seven tRNA synthetase activities (5, 6). The amino-terminal region of
the protein has been implicated in the interactions with the
multienzyme complex (5, 6). The gene encoding human lysyl-tRNA
synthetase has been localized to chromosome 16q23-q24 (7).
Since protein translation occurs in both the cytosol and mitochondria
of eukaryotic cells, the cell generally requires tRNA synthetase
activities for each amino acid in both subcellular locations. In some
cases, two distinct genes encode the cytoplasmic and mitochondrial
isoforms, e.g. human histidyl-tRNA synthetase (8).
Alternatively, one gene may encode both forms of the protein. In the
case of glycyl-tRNA synthetase, this is achieved by using alternative
transcription initiation sites, with the furthest upstream transcript
start site resulting in the addition of a mitochondrial targeting
sequence to the amino terminus of the protein (9, 10). A number of the
human mitochondrial tRNA synthetases have yet to be identified and
characterized. In yeast, the cytoplasmic and mitochondrial isoforms of
the lysyl-tRNA synthetase are encoded by two distinct genes (11, 12).
To identify and clone the gene encoding the mitochondrial form of human
lysyl-tRNA synthetase, we searched the NCBI human
EST1 data base to identify
potential ESTs that were homologous, but not identical, to the human
lysyl-tRNA synthetase. We identified a human EST cDNA sequence that
appeared to be an altered form, or alternative splicing product, of the
cytoplasmic form of the gene (AA356156). We investigated the
possibility that the alternative form of the gene encoded the
mitochondrial lysyl-tRNA synthetase.
 |
EXPERIMENTAL PROCEDURES |
Overexpression and Purification of Lysyl-tRNA
Synthetase--
Plasmid pM368 (4), containing the full-length
cytoplasmic lysyl-tRNA synthetase cloned into a derivative of E. coli expression vector pET19b, was kindly given to us by Dr.
Kiyotaka Shiba (Japanese Foundation for Cancer Research, Tokyo, Japan).
The cDNA encoding the mitochondrial lysyl-tRNA synthetase was
cloned into E. coli expression vector pET24d (Novagen). The
second codon in the cDNA, encoding leucine, was changed to one
encoding alanine to improve protein stability following expression in
E. coli, in accordance with the N-end rule (13). These
constructs were expressed in E. coli BL21(DE3) Codon Plus
(RIL) (Stratagene) at 15 °C overnight in the presence of 1 mM isopropyl-1-thio- -D-galactopyranoside to
produce lysyl-tRNA synthetase fusion proteins, with amino- or
carboxyl-terminal hexahistidine regions, which were subsequently purified using Talon metal affinity resin
(CLONTECH). The cytoplasmic form constituted
approximately 90% of the total purified protein; the mitochondrial
form constituted approximately 80% of the total purified protein (data
not shown), as determined after gel electrophoresis.
Isolation of cDNAs Encoding the Mitochondrial Lysyl-tRNA
Synthetase and the 5'-Region of the Full-length Mitochondrial
Transcript--
The 5'- portion of the lysyl-tRNA synthetase gene
encoding the mitochondrial isoform was obtained by 5'-rapid
amplification of cDNA ends (14) using total RNA isolated from human
osteosarcoma cell line 143B. cDNA, synthesized by an avian
myeloblastosis virus reverse transcription system (Promega), was
polyadenylated at the 5'-end by terminal transferase (Roche Molecular
Biochemicals). The 5' region of the mitochondrial transcript was cloned
by nested PCR using nested adapter primers (14) and nested primers
corresponding to a sequence predicted to encode the mitochondrial
targeting peptide. PCR products were cloned into the pGEMT-easy vector
(Promega) and sequenced by the Kimmel Cancer Center DNA Sequencing
Facility (Thomas Jefferson University).
Intracellular Location of Lysyl-tRNA Synthetase Isoforms--
To
investigate the localization of the proteins expressed from the two
forms of the lysyl-tRNA synthetase mRNA, the full-length mRNAs
were cloned into the mammalian expression vector pEF/myc/cyto/GFP (Invitrogen). DNA fragments encoding the full-length proteins were
cloned into NcoI and PstI sites of the vector so
that fusion proteins would be obtained with GFP added to the carboxyl
termini. The human osteosarcoma cell line 143B was transfected with
these constructs using Effectene (Qiagen). Cells on coverslips were fixed 24 h after transfection. In some cases, the cells were
immunostained with a monoclonal antibody directed against the human
cytochrome oxidase subunit I (mouse monoclonal 1D6-E1-A8; Molecular
Probes, Inc.) and appropriate fluorescent secondary antibodies (Chemicon).
In Vitro Aminoacylation Studies--
Cytoplasmic
tRNALys was synthesized by in vitro run off
transcription (15), using pLysF119 (4) as the template. Since the T7
RNA polymerase initiates with G and since the mitochondrial tRNALys begins with C, the mitochondrial
tRNALys gene was cloned so that tRNALys was
preceded by a hammerhead ribozyme (16). This plasmid was used as a
template to make a run-off transcript that was then incubated to
release a tRNA transcript starting with the correct nucleotide. The
resulting tRNAs were purified by electrophoresis through
polyacrylamide-urea gels. Aminoacylation was performed at 37 °C as
described previously (4) using 1 µM tRNA, 0.1 µCi/µl [3H]lysine (89 Ci/mmol; PerkinElmer Life Sciences), and
0.9-88 nM mitochondrial lysyl-tRNA synthetase or 5-500
nM cytoplasmic lysyl-tRNA synthetase in a total reaction
volume of 20 µl. At 3-min intervals, 4-µl aliquots were spotted on
3MM filter paper and soaked in cold 5% trichloroacetic acid to
terminate the reaction. The amount of chargeable tRNA in the purified
transcript was calculated following a time course study to determine
the plateau level for aminoacylation. These were carried out using 1.8 µM mitochondrial lysyl-tRNA synthetase with 0.2 µM cytoplasmic tRNALys transcript or 0.7 µM mitochondrial tRNALys transcript and using
cytoplasmic lysyl-tRNA synthetase with 0.4 µM cytoplasmic
tRNALys transcript or 0.8 µM mitochondrial
tRNALys transcript.
Quantitation of the Relative Amounts of mRNA Transcripts
Encoding the Cytoplasmic or Mitochondrial Forms of Lysyl-tRNA
Synthetase--
The relative amounts of each transcript in total
cellular RNA extracts from 143B cells were quantitated using the
Ribonuclease Protection Assay (RPA) system RPA II (Ambion) according to
the manufacturer's suggested protocol. A gene fragment corresponding to exon 2 (121 bp, encoding the mitochondrial targeting sequence) and
part of exon 3 (78 bp, encoding a region common to both cytoplasmic and
mitochondrial proteins) was subcloned into pGEM-Teasy. The resulting
plasmid was used as a template for in vitro transcription in
the presence of [ -32P]UTP to give a labeled fragment
of 363 nt. Different amounts of total RNA were tested in incubations
with a large excess of the 363-nt transcript. After nuclease
digestion, the protected fragments were separated by electrophoresis
through a 6% polyacrylamide gel. Signals corresponding to the
mitochondrial and cytoplasmic transcripts were quantitated by a
PhosphorImager (Molecular Dynamics, Inc., Sunnyvale, CA).
Isolation of the Genomic Region Containing the Lysyl-tRNA
Synthetase Gene--
A human blood genomic library (Novagen) was
screened with probes corresponding to different regions of the
lysyl-tRNA synthetase gene. To isolate the 5' region of the lysyl-tRNA
synthetase locus, we identified BAC clones that had been described as
containing this gene and the GEF-2 gene that, like
lysyl-tRNA synthetase, has been mapped to chromosome 16q23-q24. We
hypothesized that such clones were likely to contain the
lysyl-tRNA synthetase gene and not lysyl-tRNA synthetase pseudogenes.
Using this criterion and the NCBI Unigene identifier Hs.3100 for
lysyl-tRNA synthetase and Hs.6518 for GEF-2, with the
Caltech human Unigene information navigator, we identified BAC clones
that potentially contained the lysyl-tRNA synthetase gene. The
following BAC clones were obtained from Research Genetics: 2273 J1,
2240 F13, 2202 G16, 2202 G6, 2095 O17, 2132 O20, 2035 H4, 2192 H2, 2230 H24, 2178 D12, 2209 B14, 2256 J17, 2125 C5, and 2209 E5.
Comparison of Lysyl-tRNA Synthetase Genes among Eukaryotic
Species--
We used the following GenBankTM EST and
genomic sequences to compare the genomic or mRNA 5' sequences
encoding lysyl-tRNA synthetase: Caenorhabditis elegans
mitochondrial isoform mRNA CO9136.1, cytoplasmic isoform mRNA
AV188647.1, genomic sequence U41105.1; Drosophila melanogaster mitochondrial isoform mRNA AI516192.1,
cytoplasmic isoform mRNA AE003447.1, genomic sequence AE003447.1;
mouse mitochondrial isoform mRNA AW258396, cytoplasmic isoform
mRNA W53766; zebrafish (Danio rerio) mitochondrial
isoform mRNA AW421393, and cytoplasmic isoform mRNA,
AW421565.1.
 |
RESULTS |
Identification of Two Forms of mRNA Encoding Lysyl-tRNA
Synthetase--
BLAST searches of the NCBI/GenBankTM human
EST data base were used to identify cDNAs, homologous to
cytoplasmic lysyl-tRNA synthetase, that might potentially encode the
mitochondrial lysyl-tRNA synthetase. We identified a human EST
(GenBankTM accession number AA356156), containing the 5'
region of the cytoplasmic lysyl-tRNA synthetase gene, that appeared to
be an altered form, or represent an alternative splicing, of the
cytoplasmic form of the gene. BLAST searches of the human EST and HTGS
data bases with both bacterial and eukaryotic lysyl-tRNA sequences failed to identify other sequences related to lysyl-tRNA synthetase. This suggested that a single gene gave rise to two forms of mRNA that encode a cytoplasmic and a mitochondrial lysyl-tRNA synthetase.
Isolation of a cDNA Encoding the Mitochondrial Isoform of Human
Mitochondrial Lysyl-tRNA Synthetase--
The cDNA sequence
identified by searches of the EST data base was similar to that of the
cytoplasmic form of mitochondrial lysyl-tRNA synthetase, although it
contained an extra 180 bp inserted into the protein-coding region. This
sequence altered the reading frame so that the amino terminus of the
cytoplasmic mitochondrial lysyl-tRNA synthetase was replaced with an
amino terminus predicted by the program Mitoprot (17) to encode a
mitochondrial targeting sequence.
On the basis of the sequence of the cDNA identified by a search of
the human EST data base, we designed primers to isolate and
characterize the full-length coding region of the putative mitochondrial lysyl-tRNA synthetase and also to examine the noncoding 5' region of the mRNA. We amplified and isolated a cDNA that
encoded a full-length (625-aa) putative mitochondrial isoform of
mitochondrial lysyl-tRNA synthetase, using total RNA isolated from
human osteosarcoma cell line 143B. With the exception of the 5' region
of the mRNA, the sequence was identical to that of the cytoplasmic
lysyl-tRNA synthetase isoform, identified in
GenBankTM as gene KIAA0070 (GenBankTM
accession number D31890).
To investigate the 5' sequence of the putative mitochondrial lysyl-tRNA
synthetase transcript, we performed 5'-rapid amplification of cDNA
ends using total RNA isolated from cell line 143B. The sequence
obtained confirmed that the cDNA encoding the mitochondrial isoform
contained an upstream region corresponding to the 5' sequence of the
cytoplasmic form of the lysyl-tRNA synthetase (Fig.
1, A and B).

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 1.
5' region of mRNA encoding the
mitochondrial isoform of human lysyl-tRNA synthetase.
A, a partial DNA sequence and predicted translation of the
5'-end of the cDNA encoding the mitochondrial isoform of human
lysyl-tRNA synthetase, obtained by reverse transcriptase-PCR and
5'-rapid amplification of cDNA ends. The amino acids contained in
the cytoplasmic isoform of the enzyme are boxed. An
arrow indicates the predicted cleavage site of the
mitochondrial targeting sequence. B, a comparison of the
predicted 5' regions of the mRNAs encoding the mitochondrial
isoform of lysyl-tRNA synthetase from human (hum), mouse
(mus), C. elegans (cel), zebrafish
(dan), and Drosophila (dros) is shown.
The reading frames are represented as boxes.
White boxes, amino acid sequence contained
exclusively in cytoplasmic lysyl-tRNA synthetase. Black
boxes, amino acid sequence contained exclusively in
mitochondrial lysyl-tRNA synthetase. Diagonal
striped boxes, amino acid sequence contained in
both mitochondrial and cytoplasmic lysyl-tRNA synthetase.
Vertical striped boxes, amino acid sequence not
present in lysyl-tRNA synthetase.
|
|
Using primers homologous to the 5'- and 3'-ends of the cDNA
encoding cytoplasmic lysyl-tRNA synthetase, two full-length cDNAs encoding both the cytoplasmic and mitochondrial isoforms of
mitochondrial lysyl-tRNA synthetase were amplified by reverse
transcriptase-PCR. The sequences were identical except for a 180-bp
insertion close to the 5'-end to produce the putative mitochondrial
isoform (see Fig. 1A). This insertion introduces a sequence
encoding Lys-Trp-Trp-STOP into the cytoplasmic isoform reading frame
after the codon for Lys20. The next ATG is 24 bp downstream
from the stop codon and presumably is the initiation codon of the
mitochondrial isoform. The reading frame of the mitochondrial isoform
encodes 48 amino acids before resuming the coding sequence of the
cytoplasmic isoform at amino acid Glu22. The 48 amino acids
have the characteristics of a mitochondrial targeting sequence. The
program Mitoprot (17) predicts a mitochondrial location for this
protein and also identifies a potential mitochondrial signal cleavage
site between Lys16 and Thr17. The predicted
translation products of the cDNAs differ at their amino termini but
share a common carboxyl-terminal region of 576 amino acids. The
full-length cDNA encoding the mitochondrial lysyl-tRNA synthetase
has been deposited in GenBankTM (accession number
AF285758).
Genomic Structure of the Human Lysyl-tRNA Synthetase Gene--
A
portion of the genomic lysyl-tRNA synthetase gene was obtained from a
human genomic DNA library using probes corresponding to the full-length
cytoplasmic cDNA sequence (4). A clone (p47/4) was identified.
Southern and DNA sequence analysis showed that this contained the 3'
region of the gene (corresponding to exons 4-15 of the final sequence)
but lacked the 5' region of the gene. Repeated screening attempts
failed to find the 5' region of the gene in this library.
To obtain the 5' portion of the gene, we identified BAC clones
containing the gene encoding lysyl-tRNA synthetase, as described under
"Experimental Procedures." BAC clones were screened by Southern analysis, using a probe corresponding to the region of the cDNA encoding the putative mitochondrial targeting sequence. Eight clones
were identified that contained the 5' portion of the lysyl-tRNA synthetase gene on a 13-kb BamHI fragment. One, BAC clone
2256 J17, was selected for more detailed analyses. A combination of Southern and DNA sequence analysis confirmed that the 13-kb
BamHI fragment contained the first four exons of the
lysyl-tRNA synthetase gene. A partial genomic sequence of the
lysyl-tRNA synthetase locus was determined by direct sequencing of the
BAC clone 2256 J17 and the genomic library clone. The introns 1, 2, 3, 4, 7, and 8 were not fully sequenced, but their sizes were estimated by
restriction mapping, Southern analysis, and PCR amplification of the
BAC clones and genomic DNA.
The complete gene contained 15 exons and extended over approximately 20 kb of the genome (Fig. 2). The
intron-exon borders are shown in Table
I. A comparison of the genomic
sequence with those of the two forms of cDNA obtained showed that
the two forms of lysyl-tRNA synthetase were obtained by alternative
splicing of the first three exons of the gene (Fig.
3). The first exon encodes the
amino-terminal 20 amino acids of the cytoplasmic form of the enzyme.
The second exon encodes an open reading frame with an initiating
methionine and 48 amino acids including a region with the
characteristics of a mitochondrial targeting sequence. The cytoplasmic
form of the enzyme is encoded by an mRNA containing the first exon
spliced to the third exon, creating the cDNA for the cytoplasmic
form of the enzyme described previously (4). The mitochondrial form is
encoded by an mRNA whose 5' region consists of the first three
exons spliced consecutively. The reading frame created by the first
exon is terminated by a stop codon in the second exon. The initiating
methionine of the mitochondrial isoform is 24 bp downstream from this
stop codon (Fig. 1).

View larger version (7K):
[in this window]
[in a new window]
|
Fig. 2.
Genomic organization of the human lysyl-tRNA
synthetase gene. Shown is a diagram of the genomic organization of
the human lysyl-tRNA synthetase and the upstream KRU gene. Introns are
represented as black lines. The lysyl-tRNA
synthetase exons are shown as black boxes. The
exons of the upstream gene, KRU, are white boxes.
The arrows indicate the directions of transcription.
|
|
View this table:
[in this window]
[in a new window]
|
Table I
Exon-intron organization of the human lysyl-tRNA synthetase gene
The size of those introns not fully sequenced were estimated by PCR and
Southern analyses (estimate). Where possible these were compared to
available unfinished sequence data in the NCBI HTGS database (HTGS).
The consensus splice sites are shown above the 5' and 3' sequences.
|
|

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 3.
Production of two isoforms of the human
lysyl-tRNA synthetase by alternative splicing of the first three exons
of the gene. Shown is a diagram that illustrates the alternative
splicing that produces the two forms of human lysyl-tRNA synthetase
transcripts. A white box represents exon 1, encoding the amino terminus of the cytoplasmic isoform. Exon 2, encoding the amino terminus of the mitochondrial isoform, is
represented by a black box. Striped
boxes represent exons 3-15. Inclusion of exon 2 in a
transcript results in the major open reading frame encoding a
lysyl-tRNA synthetase with a mitochondrial targeting sequence at the
amino terminus of the protein, encoded on exon 2. Exclusion of exon 2 results in a transcript encoding the cytoplasmic isoform of the
protein, with the amino terminus encoded on exon 1.
|
|
Upstream from the initiation ATG of the human cytoplasmic lysyl-tRNA
synthetase gene, on the opposite strand, is a reading frame of 1200 bp
starting at position 243. Investigation of the corresponding cDNA
in the NCBI EST data base allowed us to construct a putative
full-length cDNA. We used this information to design primers that
were used to clone the mRNA by PCR from cDNA.
The protein encoded by the upstream reading frame, which we designated
KRU (lysyl-tRNA synthetase reading frame upstream) in Fig. 2 had no
strong homologies to known proteins. A ProfileScan analysis for protein
motifs identified a BRCT domain (residues 78-101) and a Myb domain
(residues 128-188). This protein has since been identified as a human
ortholog of Rap1 (Ref. 18; GenBankTM accession number
AF262988), a protein, localized at telomeres, that affects telomere length.
The region of chromosome 16 containing the lysyl-tRNA synthetase and
Rap1 is represented by "working draft" sequences in
GenBankTM (accession numbers AC025287 and AC011934).
There is a region of 243 bp between the two initiation codons for
lysyl-tRNA synthetase and KRU/Rap1. This region lacks a conventional
TATA sequence, as is characteristic of housekeeping genes, but
presumably contains a bidirectional promoter and is predicted to
contain several Sp1 binding domains in both orientations. A
ribonuclease protection assay analysis of mRNA isolated from human
143B cells showed that the major initiation site for the lysyl-tRNA
synthetase transcript occurs at the position corresponding to 31
(data not shown).
Analysis of Other Eukaryotic Lysyl-tRNA
Synthetases--
Analysis of the GenBankTM EST and
genomic sequence data bases (see "Experimental Procedures" for the
appropriate accession numbers) showed that it is likely that one gene
provides both cytoplasmic and mitochondrial isoforms of lysyl-tRNA
synthetase in mouse, C. elegans, D. melanogaster,
and zebrafish (D. rerio) (Fig. 1B). In each case,
the cytoplasmic form would be created by the exclusion of the second
exon, containing a mitochondrial targeting sequence during the splicing
of the primary transcript.
Both the C. elegans and D. melanogaster genomic
lysyl-tRNA synthetase sequences are predicted to contain four exons. In
C. elegans, two of the three positions of the introns in the
coding sequence are absolutely conserved with an equivalent human
intron; the third is within 3 aa (10 bp) of the equivalent site
in human DNA. Exon 1 contains the coding regions of the amino termini
of both the cytoplasmic and mitochondrial forms, since the 5'
cytoplasmic/mitochondrial boundary region of the mRNA is not
interrupted by an intron in the genome. To form the mRNA encoding
the cytoplasmic form, splicing proceeds from a point midway in exon 1 to exon 2. In Drosophila, the locations of the introns are
conserved with the human gene only for introns 1 and 2. The sequences
in the EST data base suggest that, in Drosophila, the
incorporation of the mitochondrial amino terminus might be accomplished
by initiation of transcription at exon 2.
Subcellular Localization of the Isoforms of Human Lysyl-tRNA
Synthetase--
To confirm the identities of the mRNA species
predicted to encode the two isoforms of lysyl-tRNA synthetase, they
were cloned into mammalian expression vector pEFmyc/cyto/GFP so that a
gene encoding GFP was added, in frame, to the 3'-ends of both
mRNAs. These constructs were then transfected into the human
osteosarcoma cell line 143B for transient expression studies. Cells
were fixed 24 h after transfection and examined for GFP
fluorescence or immunostained. As expected, the cytoplasmic lysyl-tRNA
synthetase-GFP fusion construct produced a diffuse, cellwide
fluorescence pattern (Fig. 4A). The putative
mitochondrial lysyl-tRNA synthetase-GFP fusion construct resulted in a
punctate pattern of fluorescence characteristic of a mitochondrial
distribution (Fig. 4C). To confirm that this localization
was mitochondrial, cells expressing the lysyl-tRNA synthetase-GFP
fusion protein were immunostained with an antibody directed against the
inner mitochondrial membrane protein COX I and a rhodamine-labeled
secondary antibody (Fig. 4B). The GFP and rhodamine staining
co-localized. Thus, the two lysyl-tRNA synthetase mRNAs encoded
enzymes that were destined for two distinct subcellular locations, the
mitochondria and the cytosol.

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 4.
Subcellular localization of human cytoplasmic
and mitochondrial lysyl-tRNA synthetase-GFP fusion proteins. Human
cell line 143B was transiently transfected with constructs containing
the two full-length lysyl-tRNA synthetase coding regions fused with
GFP. A, human cell line 143B was transiently transfected
with a pEF/myc/cyto/GFP construct containing the full-length human
cytoplasmic lysyl-tRNA synthetase coding region fused with GFP. Diffuse
GFP fluorescence was observed throughout the cytoplasm. Note the
exclusion of the majority of the fluorescence from the nucleus.
B and C, 143B cells were transfected with a
pEF/myc/cyto/GFP construct containing the full-length human
mitochondrial lysyl-tRNA synthetase coding region fused with GFP. Shown
in B is the immunofluorescence pattern of staining using a
primary antibody directed against the mitochondrial COX I protein and a
rhodamine-labeled secondary antibody. The immunofluorescence exhibits a
punctate distribution in the cytoplasm characteristic of a location in
mitochondria. The direct fluorescence of GFP in the same field of view
is shown in C. In cells expressing the mitochondrial
lysyl-tRNA synthetase-GFP construct, the GFP fluorescence co-localizes
with the immunofluorescence of COX I. This indicates that the
mitochondrial lysyl-tRNA synthetase is localized in mitochondria.
|
|
Quantitation of the Relative Amounts of the Cytoplasmic and
Mitochondrial Lysyl-tRNA Synthetase Transcripts--
The relative
amounts of the two lysyl-tRNA synthetase transcripts were quantitated
by a ribonuclease protection assay using radiolabeled sense and
antisense RNA probes designed using a cDNA sequence corresponding
to a portion of the mitochondrial lysyl-tRNA synthetase isoform (Fig.
5A). The mitochondrial form of
lysyl-tRNA synthetase was predicted to protect a fragment of 199 nt,
while the cytoplasmic form was predicted to protect a fragment of 78 nt. The 363-nt antisense probe (Fig. 5B, lane
1) was hybridized with total RNA isolated from human
osteosarcoma cell line 143B, followed by digestion with RNases A and
T1. (Fig. 5B, lanes 2 and
3). The two fragments obtained after RNase digestion were estimated to be 202 and 67 nt, consistent with the predicted lengths. The sense probe was not protected by incubation with total RNA (data
not shown). The ratio of the two transcripts remained constant over a
10-fold range of the amount of total RNA used (not shown). After
correction for the number of radiolabeled UTPs incorporated into each
probe, it was calculated that the mRNA encoding the cytoplasmic
lysyl-tRNA synthetase accounted for approximately 69 ± 3% of the
total lysyl-tRNA synthetase mRNA, while the transcript for the
mitochondrial isoform was 31 ± 3% of the total.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 5.
Quantitation of transcripts encoding isoforms
of human lysyl-tRNA synthetase. A, a schematic diagram
indicating the location of the 363-nt antisense RNA probe used for the
ribonuclease protection assay is shown. The region of the cDNA
representing exon 1 is white, and the region of the cDNA
representing exon 2 is black. The remainder of the cDNA
is striped. The probe contained sequences unrelated to
lysyl-tRNA synthetase at both its 5'- and 3'-ends as indicated by the
stippled boxes. B, after RNase
treatment the protected RNA probes were separated by electrophoresis
through a 6% polyacrylamide gel and quantitated by a PhosphorImager.
The undigested probe is shown in lane 1. 10% of
the amount of probe used in the assay was loaded in this
lane; the exposure shown for lane 1 is
shorter than that for lanes 2 and 3. Lanes 2 and 3 show the result of
hybridizing the probe with total RNA isolated from 143B cells
(lane 2, 32 µg; lane 3,
16 µg) followed by RNase digestion. The regions protected by the
mitochondrial transcript (mtKRS; 199 nt) and by the cytoplasmic
transcript (cytKRS; 78 nt) are indicated. Sizes were calculated by
comparison with a 32P-end-labeled 100-bp ladder (data not
shown).
|
|
In Vitro Aminoacylation--
The full-length mitochondrial and
cytoplasmic lysyl-tRNA synthetases were expressed in E. coli
and purified. These enzymes were used for aminoacylation assays with
gel-purified in vitro expressed transcripts for cytoplasmic
and mitochondrial tRNALys. Prior to determining the
specific activity of the enzymes, the maximum level of aminoacylation
was determined as a percentage for each transcript, using both forms of
the enzyme. As calculated by this plateau analysis, approximately 75%
of cytoplasmic tRNALys transcript and 15% of the
mitochondrial tRNALys transcript were aminoacylated by the
cytoplasmic lysyl-tRNA synthetase. The average maximum levels for
aminoacylation obtained using the mitochondrial lysyl-tRNA synthetase
were approximately 95% of the cytoplasmic tRNALys
transcript and 30% of the mitochondrial tRNALys
transcript. Although the two forms of the enzyme aminoacylate both the
cytoplasmic and the mitochondrial tRNALys transcripts, the
specific aminoacylation activity with the mitochondrial tRNALys was less than 1% of that with the cytoplasmic
tRNALys. For mitochondrial lysyl-tRNA synthetase, the
specific aminoacylation activities were 13.3 µmol/min/µmol of
protein with cytoplasmic tRNALys and 0.1 µmol/min/µmol
of protein with mitochondrial tRNALys. For cytoplasmic
lysyl-tRNA synthetase, the specific aminoacylation activities
were 3.02 µmol/min/µmol of protein with cytoplasmic tRNALys and 0.02 µmol/min/µmol of protein with
mitochondrial tRNALys.
The low aminoacylation activity of the mitochondrial
tRNALys transcript was expected, since the
mitochondrial tRNALys in vitro transcript has
been shown to have a modified hairpin structure due to the lack of a
methyl group at position 1 of adenosine 9 (19). The reason for the
higher plateau levels of aminoacylation and the 4-fold higher activity
of the mitochondrial isoform over the cytoplasmic isoform is not known.
This may reflect the difference between the cytoplasmic enzyme
expressed with an amino-terminal hexahistidine tag (4) and the
mitochondrial form with a carboxyl-terminal tag.
 |
DISCUSSION |
A variety of strategies are employed that allow a single gene to
encode proteins destined for localization in two or more eukaryotic
cellular compartments (reviewed in Refs. 20-22). Single genes may give
rise to multiple transcripts or single transcripts with multiple
translation initiation sites, or the gene transcript may undergo
alternative splicings. A single protein may also be localized to
different compartments by inefficient targeting (21) or by a chimeric
targeting sequence whose activity is modulated by post-translational
modification (23).
Where one gene encodes proteins located in both the cytoplasm and
mitochondria, the cell frequently generates two types of transcripts
from the gene. This can be accomplished by alternate transcription
start sites or by alternate splicing of the transcript. In each case,
the result is the same. The shorter transcript encodes a
nonmitochondrial form of the protein, and the longer transcript encodes
a mitochondrial targeting sequence in frame with the protein produced
from the initiating Met on the shorter transcript. The translated
proteins are identical except for the upstream targeting sequence.
In the human lysyl-tRNA synthetase gene, exon 1 encodes the
amino-terminal region of the cytoplasmic form of the enzyme. Exon 2 encodes the amino terminus of the mitochondrial protein, containing the
mitochondrial targeting sequence that is presumably cleaved upon import
of the protein into a mitochondrion. The third and subsequent exons
encode that part of the enzyme that is common to both forms of the
synthetase. The first three exons are alternatively spliced solely to
incorporate or exclude the second exon that encodes the mitochondrial
targeting sequence. This form of alternative splicing, to our
knowledge, is thus far unique among enzymes destined for more than one
cellular location. This pattern of splicing appears to be conserved
among the lysyl-tRNA synthetase genes of humans, mice, zebrafish, and
C. elegans but not S. cereviseae (Fig.
1B), based on our surveys of the EST and genomic data bases. An exception is Drosophila, where although the overall
genomic structure is maintained, the mitochondrial transcript is
predicted to commence at exon 2. A more detailed analysis of RNA
transcripts from these species is needed to confirm these predictions.
As a consequence of the splicing of exon 1 to exon 2, the mRNA
transcript encoding the mitochondrial isoform contains a 23-aa upstream
open reading frame (uORF), derived largely from exon 1, that terminates
24 nt upstream from the mitochondrial lysyl-tRNA synthetase
initiating methionine. The first 20 aa of this uORF are identical to
the amino-terminal 20 aa of the cytoplasmic isoform. Such a uORF may
have a role in the regulation of the translation of the downstream
reading frame (24, 25). The uORF in the mRNA encoding mitochondrial
lysyl-tRNA synthetase may be important, since its presence has been
conserved among the higher eukaryotes (Fig. 1B). In
Drosophila, which appears to lack the first exon in the
mitochondrial transcript, the second exon encodes a short uORF that is
unrelated to the cytoplasmic gene.
According to the scanning model of translation, the ribosome scans the
mRNA from the 5'-end and generally initiates translation at the
first ATG codon it encounters (26). The translation of the second open
reading frame on a transcript can occur by a "leaky scanning"
mechanism, where the ribosome does not always recognize the initial ATG
if the surrounding sequence is not suitable for efficient initiation.
Alternatively, reinitiation of translation can occur after the
termination of translation of the uORF (26). The latter mechanism is
more likely in the case of mitochondrial lysyl-tRNA synthetase
expression, since the sequence around the first ATG (ggaagATGgc)
contains the A at the 3-position and G at the +4-position that
characterize a strong initiating sequence (26). Further studies are
necessary to determine the mechanism for initiating translation of
human mitochondrial lysyl-tRNA synthetase.
A number of human tRNA synthetases have been described in both their
cytoplasmic and mitochondrial forms. In most cases, two genes give rise
to the separate forms of each enzyme, e.g. histidyl tRNA
synthetase (8), phenylalanyl-tRNA synthetase (27, 28), and
tryptophanyl-tRNA synthetase (29, 30). However, in the case of
glycyl-tRNA synthetase, there are two proteins derived from a single
gene (10). This is due to translation from alternate initiation codons
resulting in inclusion or exclusion of a mitochondrial targeting
sequence (10). Although other organisms contain numerous examples of
cytoplasmic and mitochondrial proteins generated by alternate splicing,
human lysyl-tRNA synthetase appears to be unique, or at least unusual,
in that the mitochondrial targeting sequence is encoded on the second
exon. More commonly, alternate transcription initiation provides
alternative 5' exons, with the mitochondrial targeting sequence being
on the first exon e.g. human dUTPase (31). An examination of
GenBankTM data bases leads us to conclude that only human
glycyl- and lysyl-tRNA synthetases are likely to have both cytoplasmic
and mitochondrial isoforms encoded by single
genes.2
Although between 15 and 30% of the mitochondrial tRNALys
transcript could be aminoacylated by high levels of enzyme, the
specific activities for aminoacylation of the mitochondrial
tRNALys with both mitochondrial and cytoplasmic enzymes
were less than 1% of those obtained with the cytoplasmic
tRNALys. This was probably due to the incorrect folding of
the in vitro mitochondrial tRNALys transcript
into a modified hairpin structure because of the lack of a methyl
group, at position 1 of adenosine 9, that is found in the native tRNA
(19). The m1A9 modification appears to be necessary for the
proper folding of the wild-type tRNALys (19, 32).
In a tRNA, the "discriminator base" at position 73 in the acceptor
stem is often important in ensuring the specific aminoacylation of the
tRNA (33). In most cases, synthetases do not efficiently aminoacylate
cognate tRNAs with substitutions at position 73. However, the
cytoplasmic isoform of the lysyl-tRNA synthetase is tolerant of
variations at the G73 discriminator base
position of cytoplasmic tRNALys and can consequently
aminoacylate the E. coli tRNALys that has A at
position 73 (4). The data presented here show that essentially the same
protein is normally required to aminoacylate mitochondrial
tRNALys with an A at the discriminator position (34) and
cytoplasmic tRNALys that has a G at the discriminator
position. In contrast, the human glycyl-tRNA synthetase, which is
encoded by a single gene and functions in both cytoplasm and
mitochondria, is unable to aminoacylate E. coli
tRNAGly (9) and shows specific requirements for the
nucleotide at the discriminator position (35). This reflects the fact
that both cytoplasmic and mitochondrial tRNAGly have the
same nucleotide at position 73.
One gene appears to encode both cytoplasmic and mitochondrial forms of
S. cereviseae cysteinyl-tRNA,2 histidyl-tRNA
(36, 37), and valyl-tRNA synthetases. Of those cases where one gene
provides both cytoplasmic and mitochondrial tRNA synthetases, S. cereviseae cytoplasmic and mitochondrial tRNACys also
conserve the discriminator base (U73), while S. cereviseae cytoplasmic and mitochondrial tRNAHis and
tRNAVal differ at the discriminator position of these
tRNAs. In the case of yeast tRNAVal, there are several
cytoplasmic tRNAs, one of which has a different discriminator
nucleotide from that common to the mitochondrial tRNAVal
and other cytoplasmic tRNAVal.
The human lysyl-tRNA synthetase also interacts with the different
secondary and tertiary structures of cytoplasmic and mitochondrial tRNALys. The mitochondrial tRNALys has a
relatively small D loop, 5 nucleotides shorter than that of cytoplasmic
tRNALys, and has also been suggested to have a different
tertiary conformation (38). The mitochondrial tRNALys has a
much larger interstem angle (~140°) between the anticodon and
acceptor stems than that of the cytoplasmic tRNALys
(80-90°) such that the overall shape of the tRNA does not conform to
the canonical L shape (38). This suggests that the human lysyl-tRNA
synthetase has considerable flexibility in regard to substrate tRNAs.
A number of mutations in the human mitochondrial tRNALys
are associated with human diseases (39, 40). Human cell lines
containing the A8344G mutation have decreased levels of aminoacylated
mitochondrial tRNALys (41). The identification of human
mitochondrial lysyl-tRNA synthetase will allow investigation into
whether pathogenic mutations in mitochondrial tRNALys
affect interactions with lysyl-tRNA synthetase and show whether defects
in these interactions contribute to the mechanism of pathogenesis.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Kiyotaka Shiba for the gift of
plasmids pM368 and pLysF119, Dr. Ya-Ming Hou for a critical reading of
the manuscript, and Dr. Ya-Ming Hou and Dr. Rich Lipman for
technical advice on the aminoacylation assays.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Biochemistry
and Molecular Pharmacology, Thomas Jefferson University, 233 S. 10th
St., Philadelphia, PA 19107. Tel.: 215-503-4845; Fax: 215-503-5393;
E-mail: Michael.King@mail.tju.edu.
Published, JBC Papers in Press, August 21, 2000, DOI 10.1074/jbc.M006265200
2
A. Palmitessa, M. P. King, and E. Davidson, unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
EST, expressed
sequence tag;
PCR, polymerase chain reaction;
GFP, green fluorescent
protein;
bp, base pair(s);
nt, nucleotide(s);
aa, amino acid(s);
uORF, upstream open reading frame.
 |
REFERENCES |
| 1.
|
Onesti, S.,
Miller, A. D.,
and Brick, P.
(1995)
Structure
3,
163-176
|
| 2.
|
Cusack, S.,
Yaremchuk, A.,
and Tukalo, M.
(1996)
EMBO J.
15,
6321-6334
|
| 3.
|
Ibba, M.,
Morgan, S.,
Curnow, A. W.,
Pridmore, D. R.,
Vothknecht, U. C.,
Gardner, W.,
Lin, W.,
Woese, C. R.,
and Soll, D.
(1997)
Science
278,
1119-1122
|
| 4.
|
Shiba, K.,
Stello, T.,
Motegi, H.,
Noda, T.,
Musier-Forsyth, K.,
and Schimmel, P.
(1997)
J. Biol. Chem.
272,
22809-22816
|
| 5.
|
Quevillon, S.,
Robinson, J. C.,
Berthonneau, E.,
Siatecka, M.,
and Mirande, M.
(1999)
J. Mol. Biol.
285,
183-195
|
| 6.
|
Rho, S. B.,
Lee, K. H.,
Kim, J. W.,
Shiba, K.,
Jo, Y. J.,
and Kim, S.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
10128-10133
|
| 7.
|
Nichols, R. C.,
Blinder, J.,
Pai, S. I.,
Ge, Q.,
Targoff, I. N.,
Plotz, P. H.,
and Liu, P.
(1996)
Genomics
36,
210-213
|
| 8.
|
O'Hanlon, T. P.,
Raben, N.,
and Miller, F. W.
(1995)
Biochem. Cell Biol.
210,
556-566
|
| 9.
|
Shiba, K.,
Schimmel, P.,
Motegi, H.,
and Noda, T.
(1994)
J. Biol. Chem.
269,
30049-30055
|
| 10.
|
Mudge, S. J.,
Williams, J. H.,
Eyre, H. J.,
Sutherland, G. R.,
Cowan, P. J.,
and Power, D. A.
(1998)
Gene (Amst.)
209,
45-50
|
| 11.
|
Mirande, M.,
Le Corre, D.,
Riva, M.,
and Waller, J. P.
(1986)
Biochimie (Paris)
68,
1001-1007
|
| 12.
|
Gatti, D. L.,
and Tzagoloff, A.
(1991)
J. Mol. Biol.
218,
557-568
|
| 13.
|
Varshavsky, A.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
12142-12149
|
| 14.
|
Frohman, M. A.
(1993)
Methods Enzymol.
218,
340-356
|
| 15.
|
Sampson, J. R.,
and Uhlenbeck, O. C.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
1033-1037
|
| 16.
|
Fechter, P.,
Rudinger, J.,
Giege, R.,
and Theobald-Dietrich, A.
(1998)
FEBS Lett.
436,
99-103
|
| 17.
|
Claros, M. G.
(1995)
Comput. Appl. Biosci.
11,
441-447
|
| 18.
|
Li, B.,
Oestreich, S.,
and de Lange, T.
(2000)
Cell
101,
471-483
|
| 19.
|
Helm, M.,
Brule, H.,
Degoul, F.,
Cepanec, C.,
Leroux, J. P.,
Giege, R.,
and Florentz, C.
(1998)
Nucleic Acids Res.
26,
1636-1643
|
| 20.
|
Martin, N. C.,
and Hopper, A. K.
(1994)
Biochimie (Paris)
76,
1161-1167
|
| 21.
|
Danpure, C.
(1997)
Trends. Cell Biol.
5,
230-238
|
| 22.
|
Small, I.,
Wintz, H.,
Akashi, K.,
and Mireau, H.
(1998)
Plant Mol. Biol.
38,
265-277
|
| 23.
|
Anandatheerthavarada, H. K.,
Biswas, G.,
Mullick, J.,
Sepuri, N. B.,
Otvos, L.,
Pain, D.,
and Avadhani, N. G.
(1999)
EMBO J.
18,
5494-5504
|
| 24.
|
Geballe, A. P.
(1996)
in
Translational Control
(Hershey, J. W. B.
, Mathews, M. B.
, and Sonenberg, N., eds)
, pp. 173-197, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 25.
|
Gray, N. K.,
and Wickens, M.
(1998)
Annu. Rev. Cell Dev. Biol.
14,
399-458
|
| 26.
|
Kozak, M.
(1999)
Gene (Amst.)
234,
187-208
|
| 27.
|
Bullard, J. M.,
Cai, Y. C.,
Demeler, B.,
and Spremulli, L. L.
(1999)
J. Mol. Biol.
288,
567-577
|
| 28.
|
Rodova, M.,
Ankilova, V.,
and Safro, M. G.
(1999)
Biochem. Cell Biol.
255,
765-773
|
| 29.
|
Frolova, L.,
Sudomoina, M. A.,
Grigorieva, A.,
Zinovieva, O. L.,
and Kisselev, L. L.
(1991)
Gene (Amst.)
109,
291-296
|
| 30.
|
Jorgensen, R.,
Sogaard, T. M.,
Rossing, A. B.,
Martensen, P. M.,
and Justesen, J.
(2000)
J. Biol. Chem.
275,
16820-16826
|
| 31.
|
Ladner, R. D.,
and Caradonna, S. J.
(1997)
J. Biol. Chem.
272,
19072-19080
|
| 32.
|
Helm, M.,
Gieg, R.,
and Florentz, C.
(1999)
Biochemistry
38,
13338-13346
|
| 33.
|
Lee, C. P.,
Mandal, N.,
Dyson, M. R.,
and RajBhandary, U. L.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
7149-7152
|
| 34.
|
Sprinzl, M.,
Horn, C.,
Brown, M.,
Ioudovitch, A.,
and Steinberg, S.
(1998)
Nucleic Acids Res.
26,
148-153
|
| 35.
|
Hipps, D.,
Shiba, K.,
Henderson, B.,
and Schimmel, P.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
5550-5552
|
| 36.
|
Chatton, B.,
Walter, P.,
Ebel, J. P.,
Lacroute, F.,
and Fasiolo, F.
(1988)
J. Biol. Chem.
263,
52-57
|
| 37.
|
Natsoulis, G.,
Hilger, F.,
and Fink, G. R.
(1986)
Cell
46,
235-243
|
| 38.
|
Leehey, M. A.,
Squassoni, C. A.,
Friederich, M. W.,
Mills, J. B.,
and Hagerman, P. J.
(1995)
Biochemistry
34,
16235-16239
|
| 39.
|
Masucci, J.,
Davidson, M.,
Koga, Y.,
Schon, E. A.,
and King, M. P.
(1995)
Mol. Cell. Biol.
15,
2872-2881
|
| 40.
|
Davidson, E.,
and King, M. P.
(1997)
Trends. Cardiovasc. Med.
7,
16-24
|
| 41.
|
Enriquez, J. A.,
Chomyn, A.,
and Attardi, G.
(1995)
Nat. Genet.
10,
47-55
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
H. Kawamata, J. Magrane, C. Kunst, M. P. King, and G. Manfredi
Lysyl-tRNA Synthetase Is a Target for Mutant SOD1 Toxicity in Mitochondria
J. Biol. Chem.,
October 17, 2008;
283(42):
28321 - 28328.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Nozaki, N. Matsunaga, T. Ishizawa, T. Ueda, and N. Takeuchi
HMRF1L is a human mitochondrial translation release factor involved in the decoding of the termination codons UAA and UAG.
Genes Cells,
May 1, 2008;
13(5):
429 - 438.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Kaminska, V. Shalak, M. Francin, and M. Mirande
Viral Hijacking of Mitochondrial Lysyl-tRNA Synthetase
J. Virol.,
January 1, 2007;
81(1):
68 - 73.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Helm
Post-transcriptional nucleotide modification and alternative folding of RNA
Nucleic Acids Res.,
February 1, 2006;
34(2):
721 - 733.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. G. Park, H. J. Kim, Y. H. Min, E.-C. Choi, Y. K. Shin, B.-J. Park, S. W. Lee, and S. Kim
From The Cover: Human lysyl-tRNA synthetase is secreted to trigger proinflammatory response
PNAS,
May 3, 2005;
102(18):
6356 - 6361.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Mahata, S. N. Bhattacharyya, S. Mukherjee, and S. Adhya
Correction of Translational Defects in Patient-derived Mutant Mitochondria by Complex-mediated Import of a Cytoplasmic tRNA
J. Biol. Chem.,
February 18, 2005;
280(7):
5141 - 5144.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Halwani, S. Cen, H. Javanbakht, J. Saadatmand, S. Kim, K. Shiba, and L. Kleiman
Cellular Distribution of Lysyl-tRNA Synthetase and Its Interaction with Gag during Human Immunodeficiency Virus Type 1 Assembly
J. Virol.,
July 15, 2004;
78(14):
7553 - 7564.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|